Cargando…
Expanded conventional first trimester screening
OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy‐associated plasma prote...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601195/ https://www.ncbi.nlm.nih.gov/pubmed/28613385 http://dx.doi.org/10.1002/pd.5090 |
_version_ | 1783264346740097024 |
---|---|
author | Carmichael, Jonathan B. Liu, Hsiao‐Pin Janik, David Hallahan, Terrence W. Nicolaides, Kypros H. Krantz, David A. |
author_facet | Carmichael, Jonathan B. Liu, Hsiao‐Pin Janik, David Hallahan, Terrence W. Nicolaides, Kypros H. Krantz, David A. |
author_sort | Carmichael, Jonathan B. |
collection | PubMed |
description | OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, alpha‐fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR). RESULTS: For T21, at a 1/300 risk cut‐off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut‐off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut‐off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut‐off, DR was 97% at a 1.2% FPR. CONCLUSION: An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell‐free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early‐onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd. |
format | Online Article Text |
id | pubmed-5601195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56011952017-10-03 Expanded conventional first trimester screening Carmichael, Jonathan B. Liu, Hsiao‐Pin Janik, David Hallahan, Terrence W. Nicolaides, Kypros H. Krantz, David A. Prenat Diagn Original Articles OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, alpha‐fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR). RESULTS: For T21, at a 1/300 risk cut‐off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut‐off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy‐associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut‐off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut‐off, DR was 97% at a 1.2% FPR. CONCLUSION: An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell‐free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early‐onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd. John Wiley and Sons Inc. 2017-07-18 2017-08 /pmc/articles/PMC5601195/ /pubmed/28613385 http://dx.doi.org/10.1002/pd.5090 Text en © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Carmichael, Jonathan B. Liu, Hsiao‐Pin Janik, David Hallahan, Terrence W. Nicolaides, Kypros H. Krantz, David A. Expanded conventional first trimester screening |
title | Expanded conventional first trimester screening |
title_full | Expanded conventional first trimester screening |
title_fullStr | Expanded conventional first trimester screening |
title_full_unstemmed | Expanded conventional first trimester screening |
title_short | Expanded conventional first trimester screening |
title_sort | expanded conventional first trimester screening |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601195/ https://www.ncbi.nlm.nih.gov/pubmed/28613385 http://dx.doi.org/10.1002/pd.5090 |
work_keys_str_mv | AT carmichaeljonathanb expandedconventionalfirsttrimesterscreening AT liuhsiaopin expandedconventionalfirsttrimesterscreening AT janikdavid expandedconventionalfirsttrimesterscreening AT hallahanterrencew expandedconventionalfirsttrimesterscreening AT nicolaideskyprosh expandedconventionalfirsttrimesterscreening AT krantzdavida expandedconventionalfirsttrimesterscreening |